AmerisourceBergen Promotes Robert P. Mauch to Executive Vice President and President of AmerisourceBergen Drug Corporation

David W. Neu to Assume Newly Created Role as Executive Vice
President of Retail Strategy and President of Good Neighbor Pharmacy®

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Feb. 4, 2015--
AmerisourceBergen Corporation (NYSE:ABC) today announced that Robert P.
Mauch, 48, PharmD, PhD, has been promoted to Executive Vice President
and President of AmerisourceBergen Drug Corporation, effective
immediately. Previously, Mauch served as AmerisourceBergen Drug
Corporation’s Senior Vice President and Chief Operating Officer. David
W. Neu will transition from his previous role as President of
AmerisourceBergen Drug Corporation to assume the newly created position
of Executive Vice President of Retail Strategy and President of Good
Neighbor Pharmacy.

“Bob has demonstrated tremendous leadership and his powerful strategic
thinking has played a significant role in enabling AmerisourceBergen to
deliver on our promise to be a global healthcare solutions leader,” said
Steven H. Collis, AmerisourceBergen’s President and Chief Executive
Officer. “In his new role, Bob’s innovative, customer-centric vision
will further our efforts to support pharmaceutical manufacturers and
healthcare providers as they work to drive the best outcomes for
patients.”

“I am very pleased that Dave will focus his considerable energy and
expertise on further strengthening AmerisourceBergen’s programs and
services for retail pharmacy,” continued Collis. “The evolving
healthcare landscape has created unprecedented opportunities to elevate
the role of community pharmacy. With Dave’s long standing commitment to Good
Neighbor Pharmacy and the independent pharmacists we serve, combined
with his demonstrated leadership in fostering innovative partnerships
throughout the pharmaceutical supply chain, we are very well positioned
to continue to drive tremendous value for all of our stakeholders.”

Prior to his role as Chief Operating Officer of AmerisourceBergen Drug
Corporation, Mauch served AmerisourceBergen in numerous positions. He
was the founder and President of Xcenda, which was acquired by
AmerisourceBergen in 2007, and has held various leadership positions at
AmerisourceBergen, including SVP, ABDC Alternate Care Sales; SVP, ABDC
Sales and SVP, ABDC Operations.

Neu has more than 30 years of industry experience holding senior
positions at General Foods Corporation, The L.A. Drug Company, Bergen
Brunswig and eventually AmerisourceBergen Drug Corporation.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel. With nearly $120 billion in annual revenue, AmerisourceBergen
is headquartered in Valley Forge, PA, and employs approximately 14,000
people. AmerisourceBergen is ranked #28 on the Fortune 500 list. For
more information, go to www.amerisourcebergen.com.

Certain of the statements contained in this presentation are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as "expect," "likely," "outlook," "forecast," "would,"
"could," "should," "can," "will," "project," "intend," "plan,"
"continue," "sustain," "synergy," "on track," "believe," "seek,"
"estimate," "anticipate," "may," "possible," "assume," variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management's
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: changes in
pharmaceutical market growth rates; price inflation in branded and
generic pharmaceuticals and price deflation in generics; declining
economic conditions, increased costs of maintaining, or reductions in
AmerisourceBergen's ability to maintain, adequate liquidity and
financing sources, and interest rate and foreign currency exchange rate
fluctuations; the disruption of AmerisourceBergen's cash flow and
ability to return value to its stockholders in accordance with its past
practices, disruption of or changes in vendor, payer and customer
relationships and terms, and the reduction of AmerisourceBergen's
operational, strategic or financial flexibility; volatility and
disruption of the capital and credit markets; economic, business,
competitive and/or regulatory developments in countries where
AmerisourceBergen does business and/or operates outside of the United
States; supplier bankruptcies, insolvencies or other credit failures;
customer bankruptcies, insolvencies or other credit failures; the loss
of one or more key customer or supplier relationships resulting in
changes to the customer or supplier mix; the retention of key customer
or supplier relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or suppliers;
risks associated with the strategic, long-term relationship between
Walgreens Boots Alliance, Inc. (including its subsidiaries Walgreen Co.
and Alliance Boots GmbH) and AmerisourceBergen, including the occurrence
of any event, change or other circumstance that could give rise to the
termination, cross-termination or modification of any of the transaction
documents among the parties (including, among others, the distribution
agreement or the generics agreement), an impact on AmerisourceBergen's
earnings per share resulting from the issuance of the warrants to
subsidiaries of Walgreens Boots Alliance, Inc., an inability to realize
anticipated benefits (including benefits resulting from participation in
the Walgreens Boots Alliance Development GmbH joint venture),
AmerisourceBergen's inability to implement its hedging strategy to
mitigate the potentially dilutive effect of the issuance of its common
stock under its special share repurchase program due to its financial
performance, the current and future share price of its common stock, its
expected cash flows, competing priorities for capital, and overall
market conditions; increasing governmental regulations regarding the
pharmaceutical supply channel; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances, federal and state
prosecution of alleged violations of related laws and regulations, and
any related litigation, including shareholder derivative lawsuits or
other disputes relating to our distribution of controlled substances;
changes in federal and state legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare, and the effect of such changes on
AmerisourceBergen's customers; frequent changes to laws and regulations
in respect of healthcare fraud and abuse and the increased scrutiny of
the federal government related thereto; qui tam litigation for alleged
violations of fraud and abuse laws and regulations and/or any other laws
and regulations governing the marketing, sale, purchase and/or
dispensing of pharmaceutical products or services and any related
litigation, including shareholder derivative lawsuits; the acquisition
of businesses that do not perform as AmerisourceBergen expects or that
are difficult for it to integrate or control or AmerisourceBergen's
inability to successfully complete any other transaction that it may
wish to pursue from time to time; risks associated with
AmerisourceBergen’s proposed acquisition of MWI, including uncertainties
as to the timing of the tender offer and the subsequent merger, the
possibility that various conditions to the consummation of the tender
offer or the merger may not be satisfied or waived, the effects of
disruption from the transactions on the respective businesses of
AmerisourceBergen and MWI and the fact that the announcement or pendency
of the transactions may make it more difficult to establish or maintain
relationships with employees, suppliers and other business partners;
risks associated with international business operations, including
non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery
laws and economic sanctions and import laws and regulations; risks
generally associated with the sophisticated information systems on which
AmerisourceBergen relies, including significant breakdown or
interruption of such systems; risks generally associated with data
privacy regulation and the international transfer of personal data;
changes in tax laws or legislative initiatives that could adversely
affect AmerisourceBergen's tax positions and/or AmerisourceBergen's tax
liabilities or adverse resolution of challenges to AmerisourceBergen's
tax positions; natural disasters or other unexpected events that affect
AmerisourceBergen's operations; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting
AmerisourceBergen's business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) and Item 1 (Business) in the
Company’s Annual Report on Form 10-K for the fiscal year ended September
30, 2014 and elsewhere in that report and (ii) in other reports.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..